UCART20x22 is under clinical development by Cellectis and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UCART20x22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UCART20x22 overview
Gene therapy is under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma including diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, primary mediastinal b-cell lymphoma and mantle cell lymphoma. The drug candidate comprises allogenic, CAR-T cells acts by targeting cells expressing both CD20, CD22. It is administered through intravenous route.
Cellectis overview
Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company pioneer’s gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors includes UCART19, UCARTS1, UCART123, UCART22, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5, s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.
For a complete picture of UCART20x22’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
